An observational study in Cytokine and Intervertebral Disc, Degenerative, sponsored by Zhongda Hospital. Recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2023-08-04.
Sponsored by Zhongda Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies in Intervertebral Disc Degeneration with a site in China — 3 open to participants now, 3 under way, none of them phase 3. Intervertebral Disc Degeneration · China.
Among the 17 studies in Intervertebral Disc Degeneration with a site in China, this one is one of 2 that started in 2023, is one of 9 observational ones, and was the 14th registered.
462 studies on the registry are indexed under Intervertebral Disc Degeneration; 100 are open to participants now.
Browse Intervertebral Disc Degeneration studies →3 of the 17 studies in Intervertebral Disc Degeneration with a site in China are open now. Recruiting first, the newest first:
Peking University Third Hospital · Sites in China
Ages 18–80
Peking University Third Hospital · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 60 Intervertebral Disc Degeneration studies recruiting now, 29 (48%) set no upper age limit and 16 (27%) stop at 75 or younger; 7 take children under 18; 5 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 2 · Phase 2 1 · Phase 3 1
First in 2010; this study’s year is marked. 2 started in 2023.
This study's planned enrollment of 40 is below the median of 119 across 170 observational studies indexed under Intervertebral Disc Degeneration.
Median enrollment 103 across the 8 interventional studies, 300 across the 9 observational. Of the 6 that completed or were terminated, 2 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 10 most frequent:
Zhongda Hospital is the lead sponsor of 104 studies on the registry; 42 are open to participants now.
Zhongda Hospital has 1 study filed under Intervertebral Disc Degeneration — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 17 studies in Intervertebral Disc Degeneration with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Low back pain (LBP) is the largest cause of morbidity in the world, and about 80% of Chinese people are affected in their lifetime. Although the prevalence of IDD gradually increases with age, IDD is very common among subjects under 30 years old. In addition to age, there are other factors, such as excessive or uneven mechanical load, obesity, genetics, nutrition, trauma and gender. In addition, it is not clear whether the heavy physical load associated with occupation is an important risk factor for IDD. Some studies have found that IDD is more common among athletes than the general population. Due to the complexity and multifactorial nature of IDD, its pathogenesis and risk factors are still unclear, which seriously hinders the rational stratification of LBP patients and limits the development of personalized treatment.
Patients with lumbar disc herniation who went to the spinal surgery department of Zhongda Hospital
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Diagnostic Test: CXCL2/CXCL8
Diagnostic Test: CXCL2/CXCL8
Diagnostic Test: CXCL2/CXCL8
Diagnostic Test: CXCL2/CXCL8
Detecte CXCL2/8 content in nucleus pulposus and peripheral blood of patients in each group
CXCL2/8 content
CXCL2/CXCL8 content of nucleus pulposus
Time frame: 1 month
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Aug 2023; primary completion for Mar 2024, 7 months later.
Of 80 observational studies under Intervertebral Disc Degeneration, half reached primary completion within 61 months of starting (the median), counting those still running; a quarter within 45 and three quarters within 84. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intervertebral Disc Degeneration →